Randomized trial · people

Thymosin alpha-1: 3 deaths vs 7 in dialysis COVID-19 pilot so far

Checked against the paper Randomized trialPublished by PepVault

The takeaway

An early look at a small dialysis trial counted fewer deaths and COVID-19-related serious events with thymosin alpha-1 than without it, but the full efficacy results were not yet in.

Kind
Randomized trial
Studied in
People
Number studied
194
Published
2023
Journal
Int Immunopharmacol

What they tested

Would thymosin alpha-1 lower the rate and severity of COVID-19, and other infections and hospital stays, in people on hemodialysis for end-stage kidney disease?

How the study was done

A randomized pilot trial at five dialysis centers in Kansas City, MO. It randomized 194 hemodialysis patients 1:1 to thymosin alpha-1 (the trial's 1.6 mg arm, given as a shot under the skin twice weekly for 8 weeks) or to a control group that did not get it, with 4 more months of follow-up.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In this early report, 3 deaths occurred in the thymosin alpha-1 group and 7 in the control group. There were 12 serious adverse effects linked to COVID-19: 5 in the thymosin alpha-1 group and 7 in the control group. Most patients got a COVID-19 vaccine at some point during the study (91 in the thymosin alpha-1 group and 76 in the control group). The antibody results and the main safety and efficacy endpoints were still to be analyzed once all patients finished.

What it doesn’t show

These are interim counts from an unfinished pilot trial, so the main questions on COVID-19 infection rate and severity are not yet answered. The control group simply did not receive the compound, and vaccine timing varied across patients during the study.

The paper

Tuthill et al. A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report. Int Immunopharmacol. 2023.

The compound

More studies on Thymosin Alpha-1

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo